Celon Pharma S.A. researchers will attend ERS Annual Congress that will be held from 6th to 10th of September 2014 in Munich. We will take this opportunity to present the latest data on innovative small-molecule inhibitors of JAK/STAT pathway and PI3Kd kinase which are being developed in our laboratories as potential therapeutics for asthma and other inflammatory diseases.
The following reports will be presented during poster sessions:
- Inhibition of JAK/STAT pathway in airway epithelium as a potential targeted therapy of asthma.
- Therapeutic potential of CPL-407-105 – novel potent JAK/STAT pathway inhibitor for the treatment of asthma.
- Preclinical characterization of CPL-302-201, a novel highly potent and selective PI3Kd inhibitor for the treatment of inflammatory disorders.
We are looking forward to meeting you in Munich!